Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

New triple-combo CFTR modulator bests Trikafta in Phase 3 trials

A new triple-combination CFTR modulator therapy for cystic fibrosis (CF) — vanzacaftor, tezacaftor and deutivacaftor — outperformed the approved therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) at reducing sweat chloride levels in Phase 3 trials. The new “vanza triple” combo was similar to Trikafta at maintaining…

Registration is open for BreatheCon 2024, Feb. 9-10

The eighth annual BreatheCon, a virtual event hosted by the Cystic Fibrosis Foundation that brings together adults with cystic fibrosis (CF), is coming up Feb. 9-10. BreatheCon 2024 will focus on the individual experience of the CF journey. Participants will have opportunities to share their own stories,…

Data awaited in Phase 3 trials of new triple-combo CFTR modulator

Results of three global clinical trials of a new triple-combination CFTR modulator therapy for cystic fibrosis (CF) —  vanzacaftor, tezacaftor and deutivacaftor — are expected shortly, Vertex Pharmaceuticals, the therapy’s developer, announced. Two of these Phase 3 trials, SKYLINE 103 (NCT05076149) and SKYLINE 102 (NCT05033080), which tested the…

Aztreonam helps preserve lung function with bacterial infections

Treatment with the inhaled antibiotic aztreonam can stabilize lung function in people with cystic fibrosis (CF) who have chronic infections of the bacterium Pseudomonas aeruginosa. That’s according to “Inhaled aztreonam lysine in the management of Pseudomonas aeruginosa in patients with cystic fibrosis: real-life effectiveness,”…

Kaftrio treatment associated with fewer sinus surgeries

People with cystic fibrosis (CF) who have chronic inflammation in the nose are less likely to need sinus surgery if they are taking the triple-combination CFTR modulator treatment Kaftrio (elexacaftor/tezacaftor/ivacaftor). That’s according to “Triple combination CFTR modulator therapy reduces the need for endoscopic sinus surgery…